Min brings 17+ years of extensive global drug development and regulatory science experience leading development and commercialization of new medicines, many of which are innovative or transformative treatments. She has contributed to the successes of Shire (acquired by Takeda), Raptor (acquired by Horizon, now Amgen), Ultragenyx, Heron, Reata (acquired by Biogen), and Intellia, while holding positions of increasing seniority. In the last two years, Min provided independent consulting to patient organizations, start-ups, small and large global organizations, private and public, on expediting medicinal product development, early approval, and patient access. Min holds a Ph.D. in molecular pharmacology and toxicology and a M.S. in regulatory science both from University of Southern California, a M.S. in pharmacology from Shanghai University of Chinese Medicine and a B.S. in pharmacy (Pharm.D. U.S. equivalent, FPGEE passed) from Nanjing University of Chinese Medicine. She is a US RAC certified member of the Regulatory Affairs Professional Society (RAPS).